Abstract: A control apparatus for an internal combustion engine in accordance with the invention includes a supercharger, a bypass passage, a flow amount adjustment device, an operational state detection portion, and a driving time determination portion. The supercharger is connected to an intake passage of an internal combustion engine and is driven by a motor. The bypass passage is provided for the intake passage in such a manner as to bypass the supercharger. By being driven electrically, the flow amount adjustment device can arbitrarily adjust a flow amount of air flowing through the bypass passage. The operational state detection portion detects an operational state of the internal combustion engine. The driving time determination portion determines a time at which the flow rate adjustment device is driven based on a result of detection performed by the operational state detection portion.

Abstract: A control apparatus for an internal combustion engine has a supercharger connected to an intake passage of the internal combustion engine and driven by a motor, a bypass passage which is provided for the intake passage in such a manner as to bypass the supercharger, flow amount adjustment device which arbitrarily adjusts a flow amount of air flowing through the bypass passage, and controller which controls the motor and the flow amount adjustment device. The flow amount adjustment device is electrically driven. The controller stops the supercharger from performing supercharging after driving the flow amount adjustment device and starting suction of air via the bypass passage.

Abstract: The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hepatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.

Abstract: The present invention provides a fused ring compound of the following formula [I] 1

Abstract: The present invention provides a process for manufacturing a semiconductor wafer capable of effectively reducing unevenness having a wavelength of 0.5 mm or more which remains on a surface of the semiconductor wafer after a first polishing step and improving flatness thereof; and a semiconductor wafer manufactured by the manufacturing process. The manufacturing process comprises: plural polishing steps including a first polishing step and a final polishing step; and a corrective polishing step performed after the first polishing step using a polishing cloth harder than that used in the first polishing step.

Abstract: The present invention provides a fused ring compound of the following formula [I] 1

Abstract: The present invention provides a fused ring compound of the following formula [I] 1

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) 1

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) 1

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) 1

Abstract: The present invention provides a process for manufacturing a semiconductor wafer capable of effectively reducing unevenness having a wavelength of 0.5 mm or more which remains on a surface of the semiconductor wafer after a first polishing step and improving flatness thereof; and a semiconductor wafer manufactured by the manufacturing process. The manufacturing process comprises: plural polishing steps including a first polishing step and a final polishing step; and a corrective polishing step performed after the first polishing step using a polishing cloth harder than that used in the first polishing step.

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) 1

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) 1

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) 1

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) wherein Z is an oxygen atom; one of R and R1 is a group of the formula wherein R3 is lower alkyl, amino or lower alkylamino, and R4, R5, R6 and R7 are the same or different and each is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy or amino, provided that at least one of R4, R5, R6 and R7 is not hydrogen atom, and the other is an optionally substituted cycloalkyl, an optionally substituted heterocyclic group or an optionally substituted aryl; and R2 is a lower alkyl or a halogenated lower alkyl, and a pharmaceutically acceptable salt thereof.

Abstract: Oxazole derivatives of the formula (I) ##STR1## wherein one of R and R.sub.1 is a methylsulfonylphenyl, an aminosulfonylphenyl or an alkylaminosulfonylphenyl, and the other is a cycloalkyl having 5 to 7 carbon atoms which is optionally substituted by lower alkyl, a thienyl optionally substituted by lower alkyl or halogen atom or a furanyl optionally substituted by lower alkyl or halogen atom, and R.sub.2 is a lower alkyl, and pharmaceutically acceptable salts thereof. The oxazole derivatives and pharmaceutically acceptable salts thereof have superior antipyretic action, analgesic action, anti-inflammatory action, and particularly, selective inhibitory action on cyclooxygenase-2 (COX-2), and are expected to be useful as an antipyretic agent, an analgesic agent and an anti-inflammatory agent with less side-effects such as disorders in the digestive tract.

Abstract: A heterocyclic aromatic oxazole compound of the formula (I) ##STR1## wherein Z is an oxygen atom; one of R and R.sub.1 is a group of the formula ##STR2## wherein R.sub.3 is lower alkyl, amino or lower alkylamino, and R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are the same or different and each is hydrogen atom, halogen atom, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy or amino, provided that at least one of R.sub.4, R.sub.5, R.sub.6 and R.sub.7 is not hydrogen atom, and the other is an optionally substituted cycloalkyl, an optionally substituted heterocyclic group or an optionally substituted aryl; and R.sub.2 is a lower alkyl or a halogenated lower alkyl, and a pharmaceutically acceptable salt thereof.

Abstract: Oxazole derivatives of the formula (I) ##STR1## wherein one of R and R.sub.1 is a methylsulfonylphenyl, an aminosulfonyl-phenyl or an alkylaminosulfonylphenyl, and the other is a cycloalkyl having 5 to 7 carbon atoms which is optionally substituted by lower alkyl, a thienyl optionally substituted by lower alkyl or halogen atom or a furanyl optionally substituted by lower alkyl or halogen atom, and R.sub.2 is a lower alkyl, and pharmaceutically acceptable salts thereof. The oxazole derivatives and pharmaceutically acceptable salts thereof have superior antipyretic action, analgesic action, anti-inflammatory action, and particularly, selective inhibitory action on cyclooxygenase-2 (COX-2), and are expected to be useful as an antipyretic agent, an analgesic agent and an anti-inflammatory agent with less side-effects such as disorders in the digestive tract.

Abstract: An improved controller for controlling fuel injection in an internal combustion engine. The engine includes a fuel injection valve for directly injecting fuel into a combustion chamber. A fuel pressure sensor detects the fuel pressure within the injection valve. An ECU computes opening time of the injection valve and closing time of the injection valve based on a required fuel injection amount. The ECU computes a reference time at which the pressure in the combustion chamber reaches the injection pressure of the injection valve based on the detected fuel pressure. If necessary, the ECU advances the computed opening time and the computed closing time. As a result, the fuel injection from the injection valve is finished before the reference time. This prevents matter inside the combustion chamber from entering the fuel injection valve, and it guarantees that fuel will be able to exit the fuel injection valve during injection.

Abstract: An improved apparatus and method for controlling fuel injection in an internal combustion engine. The engine includes main-injection valves for directly injecting fuel into corresponding combustion chambers and a sub-injection valve for injecting fuel into a surge tank. The engine is able to perform a plurality of fuel injection modes. An ECU selects a homogeneous fuel injection mode, in which the injected fuel is evenly mixed with air supplied into the combustion chamber, from the plurality of fuel injection modes when the engine is being cranked and fuel injected from the main-injection valve will not adequately vaporize in the combustion chamber. The ECU controls the first and second injection valves according to the selected fuel injection mode. This improves engine starting and increases fuel efficiency.